Table 1.
Baseline characteristics of included studies.
| Trials | Phase | Treatments | Participants | Median DFS (mo) |
Median OS (mo) |
3-yr DFS |
3-yr OS |
Local recurrence |
Distant metastasis |
Brain metastasis |
Death due to cancer |
Grade 3–5 AE |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CALGB 9734 | 3 | Observation | 18 | 16.8 | 33.2 | NR | NR | 6 | 7 | 4 | NR | NR |
| PORT | 19 | 33.7 | 41.5 | NR | NR | 5 | 6 | 1 | NR | NR | ||
| Lung ART | 3 | Observation | 249 | 22.8 | NR | 43.8% | 68.5% | 70 | 71 | 27 | 87/102 | 39 |
| PORT | 252 | 30.5 | NR | 47.1% | 66.5% | 36 | 71 | 34 | 68/99 | 63 | ||
| PORT-C | 3 | Observation | 180 | 18.6 | 81.5 | 32.7% | 82.8% | 48 | 84 | NR | 42/47 | 0 |
| PORT | 184 | 22.1 | NR | 40.5% | 78.3% | 39 | 91 | NR | 47/50 | 1 |
AE = adverse events, ART = adjuvant radiotherapy, CALGB = cancer and Leukemia Group B, DFS = disease-free survival, NR = not reported, OS = overall survival, PORT = postoperative radiotherapy, PORT-C = postoperative radiotherapy-China.